

#6

09835699.081701




FIG.1A




FIG. 1B




FIG.1C




FIG.2A




FIG.2B




FIG.2C




FIG.2D





FIG. 3



□ 1.56 µg; ○ 0.78 µg V1J:gD DNA; ◆ saline

△ 200; 100; 25; 12.5; 6.25; 3.13 µg

FIG. 4




FIG. 6




FIG. 5




FIG. 7

Group ^a	Survivors/ Total (%)	Mean Day to Death	Paralyzed/ Total (%)	Vaginal Virus Titer ^b		
				Day 2 ^c	Day 4	Day 6
Vaccine, 10 μ g	8/10 (80)	12.5 \pm 0.7	5/10 (50)	3.8 \pm 1.9	2.3 \pm 1.2	<1.5 \pm 0.0
Vaccine, 100 μ g	10/10 (100)†	>21	0/10 (0)*	3.0 \pm 1.3 \emptyset	2.0 \pm 0.7†	<1.5 \pm 0.0
Placebo	6/10 (60)	14.8 \pm 4.0	8/10 (80)	5.0 \pm 2.3	3.1 \pm 1.4	1.6 \pm 0.3

^a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

^b Log₁₀ cell culture infections doses per ml, determined from vaginal swabs.

^c After virus inoculation.

* P<0.001.

† P=0.08, \emptyset P=0.06.

FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG.11




FIG.12




FIG.13A




FIG.13B




FIG.14A




FIG.14B




FIG.15A




FIG.15B